Beers, Andrew
Brown, James
Chang, Ken
Hoebel, Katharina
Patel, Jay
Ly, K. Ina
Tolaney, Sara M.
Brastianos, Priscilla
Rosen, Bruce
Gerstner, Elizabeth R.
Kalpathy-Cramer, Jayashree
Funding for this research was provided by:
National Institutes of Health (T90DA022759/R90DA023427)
National Institute of Biomedical Imaging and Bioengineering (5T32EB1680)
National Institutes of Health (U01CA154601)
National Institutes of Health (U24CA180927)
National Institutes of Health (U24CA180918)
National Institute of Biomedical Imaging and Bioengineering (P41EB015896)
Article History
First Online: 23 June 2020
Compliance with Ethical Standards
:
: JKC is a consultant/advisory board member for Infotech, Soft. ERG is an advisory board member for Blue Earth Diagnostics. BR is on the advisory board for ARIA, Butterfly, Inc., DGMIF (Daegu-Gyeongbuk Medical Innovation Foundation), QMENTA, Subtle Medical, Inc., is a consultant for Broadview Ventures, Janssen Scientific, ECRI Institute, GlaxoSmithKine, Hyperfine Research, Inc., Peking University, Wolf Greenfield, Superconducting Systems, Inc., Robins Kaplin, LLC, Millennium Pharmaceuticals, GE Healthcare, Siemens, Quinn Emanuel Trial Lawyers, Samsung, Shenzhen Maternity and Child Healthcare Hospital, and is a founder of BLINKAI Technologies, Inc. PB is a consultant for Angiochem, Lilly, Tesaro, Genentech-Roche; has received honoraria from Genentech-Roche and Merckl and has received institutional funding from Merck and Pfizer. SMT receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odenate, and Nektar. SMT has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Tesaro, and Nanostring. The other authors declare no competing interests.